GlaxoSmithKline Pharmaceuticals Stock: Earnings Estimates
GLAXO.NSFor GlaxoSmithKline Pharmaceuticals, analysts expect revenue of $469.17M (up 13.8%) and adjusted earnings per share of $0.76 (up 17.8%) on average for fiscal year 2027. For 2028 they expect revenue of $527.56M (up 12.4%) and adjusted earnings per share of $0.88 (up 15.1%). That is the average of the estimates of 5 analysts.
Daily figure as of 22 Nov 2026
Reported and Expected
| Fiscal year | Type | Revenue | Growth | Net income | Net margin | EPS | Analysts |
|---|---|---|---|---|---|---|---|
| 2024 | Reported | $371.38M | 6.7% | $63.66M | 17.1% | $0.38 | |
| 2025 | Reported | $402.05M | 8.3% | $100.09M | 24.9% | $0.59 | |
| 2026 | Reported | $412.37M | 2.6% | $111.79M | 27.1% | $0.66 | |
| 2027 | Estimate | $469.17M | 13.8% | $129.28M | 27.6% | $0.76 | 5 |
| 2028 | Estimate | $527.56M | 12.4% | $148.75M | 28.2% | $0.88 | 5 |
Earnings per share in the estimates are usually adjusted, the way analysts calculate them. The reported figure is the statutory one and can therefore differ.
What the Estimates Show
In the report of 3 Nov 2026, earnings per share came in 20% above the expectation. In 4 of 7 quarters, GlaxoSmithKline Pharmaceuticals missed the analysts' expectation for revenue and beat it twice. The expected revenue growth for 2027 of +13.8% is above the average of fiscal years 2021 to 2026 of +5.7% per year.
In 3 of 4 quarters, GlaxoSmithKline Pharmaceuticals met the analysts' expectation for earnings per share within 2% and beat it once. The expected net margin rises from 27.6% in 2027 to 28.2% in 2028. Earnings per share are expected to grow faster than revenue in 2027, by 17.8% against 13.8%.
A reported figure within 2% of the expectation counts as in line.
How GlaxoSmithKline Pharmaceuticals Compares
Among the 26 other stocks in the Drug Manufacturers (General) industry with a forward P/E, the median is 15.7. At 35.2, GlaxoSmithKline Pharmaceuticals is above it.
Estimates of Industry Peers
Among industry peers, analysts expect the strongest revenue growth at Grifols (+6.4%) and the weakest at CSPC Pharmaceutical Group (−6.6%).
| Stock | Expected revenue growth | Forward P/E |
|---|---|---|
| Zhangzhou Pientzehuang Pharmaceutical. | +4.1% | 37.3 |
| CSPC Pharmaceutical Group | −6.6% | 11.9 |
| Grifols | +6.4% | 10.4 |
| Ono Pharmaceutical | −2.6% | 16.5 |
| Virbac | +6.2% | 14.8 |
Revenue growth here means the next fiscal year against the current one, both analyst averages.
Forecast and Fair Value
The forward P/E of GlaxoSmithKline Pharmaceuticals is 35.2, below the P/E on statutory earnings of the last twelve months (40.3). It uses the earnings analysts expect for the next twelve months. MEQIRI's fair value for GlaxoSmithKline Pharmaceuticals is $14.36, 51.2% below the share price. Its cash flow part uses the analysts' estimates for the first 2 years.
Why There Is No Price Target Here
MEQIRI deliberately does not show price targets or buy and sell recommendations, because they are opinions about the future share price. Revenue and earnings, by contrast, can be checked against every report.
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026; valuation signal Overvalued since 22 Nov 2026
- Price: closing price of 20 Nov 2026
- Amounts in US dollars at the ECB reference rate of 20 Nov 2026 ($1 = ₹92.6752)
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2026. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
